THE INFLUENCE OF THE BASE PHARMACOTHERAPY AND COMBINATIONS OF METABOLIC DRUGS ON QUAL- ITY OF LIFE OF PATIENTS WITH ARTERIAL HYPERTEN- SION ASSOCIATED WITH INSULIN RESISTANCE
25-30% of adult population in the economically developed countries, including Ukraine, have arterial hypertension (AH). During the last 10-15 years there is high interest to metabolic disorders in arterial hypertension. By estimations of most experts, a leading factor in forming the symptoms of the metabolic syndrome is insulin resistance (IR). In development of AH in insulin resistance the complex influence of hyperinsulinemia and concomitant metabolic disorders play the leading part. That is why the search of etiological factors and links of path- ogenis of AH is extremely actual since it can promote in determination of new ways of its effective pharmaco- therapy. The article presents the own information about the changes of the life quality indexes of patients with arterial hypertension associated with insulin resistance when taking metabolic drugs (rosiglitazone, metformin and thyotriazolin) included in standard pharmacotherapy (candesartan + perindopril).